Asset: Potent and selective oral sEH small-molecule inhibitor
Development Stage: PCC nomination
Indication: Diabetic Peripheral Neuropathic Pain, Osteoarthritis
Key Asset Highlights:
- Exhibits high target selectivity and potent inhibitory potency against soluble epoxide hydrolase (sEH), a key enzyme regulating inflammatory and pain signaling pathways, with excellent target specificity and minimal off-target liabilities.
- Effectively elevates endogenous epoxyeicosatrienoic acid levels and suppresses persistent neuroinflammation, delivering robust analgesic and anti-inflammatory efficacy in preclinical models of diabetic peripheral neuropathic pain.
- Significantly mitigates joint inflammation, cartilage degradation and nociceptive responses in osteoarthritis models, showing superior therapeutic potential for chronic inflammatory pain disorders.
- Demonstrates distinct differentiated advantages over conventional analgesics, avoiding the addictive risks and systemic side effects of opioid and NSAID-based therapies.
- Features favorable oral pharmacokinetic profiles and a wide therapeutic safety window, supporting sustained oral administration and long-term chronic disease management.
- Protected by a comprehensive intellectual property portfolio, ensuring stable and exclusive global development and commercialization rights for inflammatory pain treatment indications.
If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
